SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs quarterly earnings beat expectations and its raised outlook, powered by rapid commercial AI growth that surpassed U.S. government revenue for the first time, are driving discussion. Bulls point to strong execution, while bears argue the growth was already priced in and the stocks weak reaction reflects its high valuation and broader tech-market pressure.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples quarterly earnings beat estimates, but shares sold off as traders focused on margin pressure from rising memory costs, slower growth guidance, and weaker China, iPad, and wearables results. The community is split between buyers pointing to strong iPhone sales and bulls arguing the drop is an overreaction, and skeptics concerned about valuation and the outlook.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial reached its prespecified 80th event, triggering final analysis and putting the pending GPS topline results in focus. The stocks sharp decline since the milestone has fueled debate over profit-taking and risk reduction ahead of a binary readout versus unsubstantiated claims of manipulation or a data leak; no results have been disclosed.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells all-stock agreement to acquire Lumentum is driving attention, with traders criticizing the dilution, price and long closing timeline as the stock sells off. Others argue the deal strengthens Marvells position in AI data-center optical connectivity and could pay off over the longer term.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned equity and debt fundraising for its AI infrastructure buildout has driven the selloff, with traders worried about shareholder dilution, rising leverage, and whether AI spending will pay off. Others argue the financing was already outlined and see the sharp reaction as an overreaction or a buying opportunity.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs quarterly earnings report is the focus after a sharp selloff in the shares and broader semiconductor weakness following Intels warning. Traders are divided on whether AI-chip demand and forward guidance can restore confidence or whether high valuation and the recent tech-sector pressure will weigh on the stock despite a strong report.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Small-cap rotation and IWMs relative strength against pressured megacap technology stocks dominate the discussion, with traders debating whether the rebound signals a sustained recovery or a temporary bounce. Bulls point to improving small-cap momentum and seasonal optimism, while bears cite choppy trading and uncertainty around interest rates, elections, and geopolitical risks.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

DIA drew attention as the Dow held up better than tech-heavy indexes amid concern over AI spending and valuations, with traders debating whether the markets bounce could last and many continuing to favor shorts. Lower oil on hopes for U.S.-Iran diplomacy also featured in the broader market discussion.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells announced all-stock acquisition of Lumentum is driving attention, with LITE shares plunging as traders focus on the fixed exchange ratio, exposure to Marvells falling share price, and the long wait for closing. Many criticize the deal as unfavorable to LITE shareholders and question whether it will be approved, while others see the selloff as an overreaction and point to the companies AI-optics strategic fit.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergents Q3 results and reduced full-year outlook are driving discussion, with traders focused on weak revenue, declining NARCAN sales and delayed or uncertain government orders. Bears question the turnaround and debt outlook, while bulls point to cost cuts and potential future CYFENDUS replenishment as offsets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers

Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million.
Tenax Therapeutics (NASDAQ:TENX)read more...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million.
Tempest Therapeutics (NASDAQ:TPST) stock moved upwards byread more...

Tempest Doubles Down on In Vivo CAR-T with Second Delivery Platform

Tempest Therapeutics (NASDAQ:TPST) is moving aggressively to build a multi-platform in vivo CAR-T business, securing an exclusive option to license a clinical-stage CD7-targeted lentiviral technology just months before its own next-generation CAR-T program is expected to enter the clinic.

Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket

Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.read more...

Tempest Therapeutics (TPST) Stock Climbs Over 66% After Hours: Here's Why

Tempest Therapeutics shares soared 66.53% after hours Tuesday following an exclusive option agreement expanding its in vivo CAR-T pipeline.read more...

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's after-market session. The company's market cap stands at $12.9 million.
Jupiter Neurosciences (NASDAQ:JUNS) stockread more...

New Strong Buy Stocks for April 10th

ESCA, GRDN, TPST, ASTE and ECG have been added to the Zacks Rank #1 (Strong Buy) List on April 10th, 2026. 

Tempest Therapeutics (NASDAQ:TPST) CEO Matthew Angel Acquires 231,482 Shares

Tempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) CEO Matthew Angel acquired 231,482 shares of the business's stock in a transaction on Tuesday, March 24th. The shares were purchased at an average cost of $2.16 per share, for a total transaction of $500,001.12. Following the completion of...

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction

Equity

The transaction is expected to close in early 2026, provided it receives all required approvals. 


Why Tempest Therapeutics (TPST) Stock Is Down 45% Today

Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience.read more...

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Tempest Therapeutics Inc

Neutral Sentiment

In this photo illustration, the Tempest Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The transaction is expected to close in early 2026, provided it receives all required approvals. 

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$0.472
Prev Close	$0.4955
Open	$0.50
Dividend Yield	0.00%
50-Day Moving Average	$0.8186
Beta	1.57
Avg. Volume	7.33M
PE Ratio	-0.11

52-Week High	$10.45
52-Week Low	$0.4902
Market Capitalization	$9.91M
EPS (Annual)	-$6.33
Price to Book	-7.26
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

TPST Fundamentals